[Therapeutic options to reduce arterial stiffness in chronic kidney disease]

Area of Science:

• Nephrology
• Cardiology
• Vascular Biology

Background:

• Chronic kidney disease (CKD) is linked to heightened cardiovascular risk.
• Uremic toxins contribute to vascular damage and aortic stiffening in CKD patients.
• Oxidative stress and endothelial dysfunction are key mechanisms in aortic stiffening.

Purpose of the Study:

• To review therapeutic strategies for reducing aortic stiffness in CKD.
• To explore the potential of reducing aortic stiffness to mitigate cardiovascular risk.
• To examine the association between reduced aortic stiffness and improved survival in end-stage kidney disease (ESKD).

Main Methods:

• Literature review of studies on aortic stiffness in CKD.
• Analysis of the role of uremic toxins, oxidative stress, and endothelial dysfunction.
• Evaluation of therapeutic interventions targeting aortic stiffness.

Main Results:

• Aortic stiffness is a significant cardiovascular risk factor and biomarker in CKD.
• Therapeutic reduction of aortic stiffness may improve patient survival.
• Several therapeutic avenues are being investigated to target aortic stiffness.

Conclusions:

• Aortic stiffening is a critical factor in CKD-associated cardiovascular morbidity and mortality.
• Targeting aortic stiffness represents a promising therapeutic strategy for CKD patients.
• Further research is needed to establish effective treatments for reducing aortic stiffness and cardiovascular risk in CKD.